Study study type PathologyT1T0Patientssample sizesROB Results

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
bevacizumab
ORIENT-32, 2021
 
NCT03794440
RCTmHCC - 1st line (L1)Sintilimab plus IBI305 (bevaciumab biosimilar)Sorafenibpatients with unresectable, locally advanced, or metastatic hepato cellular carcinoma, with a diagnosis that was histologically, cytologically, or clinically confirmed, who had received no previous systemic therapy for advanced or metastatic disease, or were unsuitable for radical surgery or had local treatment stage B380 / 191low
conclusif
  • demonstrated 43 % decrease in deaths (OS) (PE)